[go: up one dir, main page]

WO1999000150A3 - Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor - Google Patents

Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor Download PDF

Info

Publication number
WO1999000150A3
WO1999000150A3 PCT/US1998/013398 US9813398W WO9900150A3 WO 1999000150 A3 WO1999000150 A3 WO 1999000150A3 US 9813398 W US9813398 W US 9813398W WO 9900150 A3 WO9900150 A3 WO 9900150A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibody
human insulin
insulin receptor
brain barrier
vivo
Prior art date
Application number
PCT/US1998/013398
Other languages
French (fr)
Other versions
WO1999000150A9 (en
WO1999000150A2 (en
Inventor
William M Pardridge
Original Assignee
Univ California
William M Pardridge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, William M Pardridge filed Critical Univ California
Priority to AU82698/98A priority Critical patent/AU8269898A/en
Publication of WO1999000150A2 publication Critical patent/WO1999000150A2/en
Publication of WO1999000150A3 publication Critical patent/WO1999000150A3/en
Publication of WO1999000150A9 publication Critical patent/WO1999000150A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

[125I]-Aβ1-40 was mono-biotinylated and conjugated to a blood-brain barrier drug delivery and brain targeting system comprised of a complex of the 83-14 monoclonal antibody (MAb) to the human insulin receptor, which is tagged with streptavidin (SA) to produce a marked increase in rhesus monkey brain uptake of the [125I]-bio-Aβ1-40 at 3 hours following intravenous injection compared to no measurable brain uptake of [125I]-bio-Aβ1-40 in the absence of a BBB drug.
PCT/US1998/013398 1997-06-27 1998-06-26 Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor WO1999000150A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU82698/98A AU8269898A (en) 1997-06-27 1998-06-26 Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5106597P 1997-06-27 1997-06-27
US60/051,065 1997-06-27

Publications (3)

Publication Number Publication Date
WO1999000150A2 WO1999000150A2 (en) 1999-01-07
WO1999000150A3 true WO1999000150A3 (en) 1999-04-01
WO1999000150A9 WO1999000150A9 (en) 1999-05-14

Family

ID=21969115

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/013398 WO1999000150A2 (en) 1997-06-27 1998-06-26 Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor

Country Status (2)

Country Link
AU (1) AU8269898A (en)
WO (1) WO1999000150A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486399B2 (en) 2011-12-02 2013-07-16 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
US8497246B2 (en) 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8834874B2 (en) 2009-10-09 2014-09-16 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
US8974791B2 (en) 2007-07-27 2015-03-10 Armagen Technologies, Inc. Methods and compositions for increasing α-L-iduronidase activity in the CNS
US9533055B2 (en) 2009-03-18 2017-01-03 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
JP2003516745A (en) * 1999-12-13 2003-05-20 ケンブリッジ アンティボディー テクノロジー リミティド Brain specific binding members
WO2002021141A2 (en) * 2000-09-06 2002-03-14 Aventis Pharma S.A. Methods and compositions for diseases associated with amyloidosis
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (en) 2000-12-06 2002-07-02 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
EP1387698B1 (en) * 2001-05-04 2007-11-14 Nymox Corporation Method of preventing cell death using antibodies to neural thread proteins
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
EP2292271A3 (en) 2001-10-10 2011-09-14 BioGeneriX AG Remodelling and glycoconjugation of an antibody
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
ES2420581T3 (en) 2003-03-14 2013-08-26 Biogenerix Gmbh Branched water soluble polymers and their conjugates
US7691603B2 (en) 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
EP2338333B1 (en) 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylation methods and proteins/peptides produced by the methods
CA2524936A1 (en) 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
PE20050627A1 (en) 2003-05-30 2005-08-10 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
MXPA06005732A (en) 2003-11-24 2006-08-17 Neose Technologies Inc Glycopegylated erythropoietin.
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
ES2560657T3 (en) 2004-01-08 2016-02-22 Ratiopharm Gmbh O-linked glycosylation of G-CSF peptides
KR20070008645A (en) 2004-05-04 2007-01-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 O-linked protein glycoforms of polypeptides and methods for their preparation
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
WO2006066049A2 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
MX2007008229A (en) 2005-01-10 2007-09-11 Neose Technologies Inc Glycopegylated granulocyte colony stimulating factor.
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2008011633A2 (en) 2006-07-21 2008-01-24 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
PL2144923T3 (en) 2007-04-03 2013-12-31 Biogenerix Ag Methods of treatment using glycopegylated g-csf
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CN101778859B (en) 2007-06-12 2014-03-26 诺和诺德公司 Improved process for the production of nucleotide sugars
PL2182983T3 (en) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
CA2715465C (en) 2008-02-27 2017-03-21 Novo Nordisk A/S Conjugated factor viii molecules
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
AU2010306940A1 (en) 2009-10-12 2012-06-07 Smith, Larry Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
JP2020508049A (en) 2017-02-17 2020-03-19 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Engineered transferrin receptor binding polypeptide
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000834A1 (en) * 1986-07-30 1988-02-11 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
WO1994002178A1 (en) * 1992-07-27 1994-02-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeting of liposomes to the blood-brain barrier
EP0599303A2 (en) * 1992-11-27 1994-06-01 Takeda Chemical Industries, Ltd. Peptide conjugate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000834A1 (en) * 1986-07-30 1988-02-11 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
WO1994002178A1 (en) * 1992-07-27 1994-02-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeting of liposomes to the blood-brain barrier
EP0599303A2 (en) * 1992-11-27 1994-06-01 Takeda Chemical Industries, Ltd. Peptide conjugate

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
B.V.ZLOKOVIC ET AL.: "Brain uptake of circulating apolipoproteins J and E complexedto Alzheimer's amyloid ß", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 205, no. 2, 15 December 1994 (1994-12-15), ORLANDO, US, pages 1431 - 1437, XP002090773 *
MARTEL, C. L. ET AL: "Transport of apolipoproteins E and J at the blood - brain barrier. Relevance to Alzheimer's disease", S.T.P. PHARMA SCI., VOL. 7, NO. 1, PAGE(S) 28-36, January 1997 (1997-01-01) - February 1997 (1997-02-01), XP002090769 *
MARTEL, CYNTHIA L. ET AL: "Blood - brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid ß in guinea pigs", NEUROSCI. LETT., VOL. 206, NO. 2,3, PAGE(S) 157-60, 1996, XP002090771 *
PARDRIDGE, WILLIAM M. ET AL: "Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood - brain barrier in vivo in the primate.", PHARMACEUTICAL RESEARCH, 1995, VOL. 12, NO. 6, PAGES 807-816., XP002090768 *
PODUSLO, JOSEPH F. ET AL: "Permeability and residual plasma volume of human, Dutch variant, and rat amyloid ß-protein 1-40 at the blood - brain barrier", NEUROBIOL. DIS., 1997, VOL. 4, NO. 1, PAGE(S) 27-34, XP002090770 *
SAITO Y ET AL: "Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex.", PROC NATL ACAD SCI U S A, OCT 24 1995, VOL. 92, NO. 22, PAGE(S) 10227-31, XP002090767 *
WU, DAFANG ET AL: "Drug targeting of a peptide radiopharmaceutical through the primate blood - brain barrier in vivo with a monoclonal antibody to the human insulin receptor", J. CLIN. INVEST., VOL. 100, NO. 7, PAGE(S) 1804-1812, 1 October 1997 (1997-10-01), XP002090766 *
ZLOKOVIC B V ET AL: "Glycoprotein 330-megalin: Probable role in receptor -mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood - brain and blood-cerebrospinal fluid barriers.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, VOL. 93, NO. 9, 1996, PAGE(S) 4229-4234., XP002090772 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8759297B2 (en) 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
US8497246B2 (en) 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
US10144783B2 (en) 2006-08-18 2018-12-04 Armagen, Inc. Macromolecular compositions that cross the blood-brain barrier and methods of use thereof
US8753610B2 (en) 2006-08-18 2014-06-17 Armagen Technologies, Inc. Methods for diagnosing CNS disorders with fusion antibodies that cross the blood-brain barrier in both directions
US8974791B2 (en) 2007-07-27 2015-03-10 Armagen Technologies, Inc. Methods and compositions for increasing α-L-iduronidase activity in the CNS
US9567400B2 (en) 2007-07-27 2017-02-14 Armagen Technologies, Inc. Methods and compositions for increasing α-L-iduronidase activity in the CNS
US11512145B2 (en) 2007-07-27 2022-11-29 Armagen, Inc. Methods and compositions for increasing alpha-L-iduronidase activity in the CNS
US10202467B2 (en) 2007-07-27 2019-02-12 Armagen, Inc. Methods and compositions for increasing α-L-iduronidase activity in the CNS
US9533055B2 (en) 2009-03-18 2017-01-03 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
US10011651B2 (en) 2009-10-09 2018-07-03 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
US8834874B2 (en) 2009-10-09 2014-09-16 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
US11028156B2 (en) 2009-10-09 2021-06-08 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
US12043661B2 (en) 2009-10-09 2024-07-23 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
US9975955B2 (en) 2011-12-02 2018-05-22 Armagen, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
US8715661B2 (en) 2011-12-02 2014-05-06 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
US8486399B2 (en) 2011-12-02 2013-07-16 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
US8920801B2 (en) 2011-12-02 2014-12-30 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

Also Published As

Publication number Publication date
WO1999000150A9 (en) 1999-05-14
WO1999000150A2 (en) 1999-01-07
AU8269898A (en) 1999-01-19

Similar Documents

Publication Publication Date Title
WO1999000150A3 (en) Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
NO20015584D0 (en) Long-lasting insulin trophic peptides
CA2066244A1 (en) Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
PE20071063A1 (en) STABLE PROTEIN FORMULATIONS
ES2109891A1 (en) Disposable syringe with two variable volume chambers
WO2000069900A3 (en) Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
FR2736553B1 (en) INJECTION SYRINGE, IN PARTICULAR LIQUID MEDICAL PRODUCTS, WITH MOBILE NEEDLE PROTECTOR
WO2005097202A3 (en) Use of serum albumin binding peptides conjugates for the preparation of a medicament
MY124695A (en) Novel composition and use.
AU6135399A (en) Intravenous infusion needle with soft body
FR2748588B1 (en) DEVICE COMPRISING AT LEAST ONE ARRAY OF NEURONES FOR DETERMINING THE QUANTITY OF A SUBSTANCE TO BE ADMINISTERED TO A PATIENT, IN PARTICULAR INSULIN
IL136512A0 (en) Intravenous infusion administration set
WO1999024074A3 (en) Novel conjugates of opioids and endogenous carriers
WO2004112838A3 (en) Codrugs of diclofenac
AP1901A (en) Pharmaceutical composition for modified release insulin sensitiser.
WO2003037272A3 (en) Thymosin alpha 1 peptide/polymer conjugates
WO2003009870A1 (en) Remedies for mammary cancer
ID23424A (en) GLIKOKONJUGUS OF 20 (S) -CAMPTOTESIN
WO2000070665A3 (en) Long lasting anti-angiogenic peptides
IL161665A0 (en) Method of administering a thymosin alpha 1 peptide
WO2002085418A3 (en) Tc and re labeler radioactive glycosylated octreotide derivatives
MY138246A (en) Treatment of diabetes with thiazolidione and sulphonylurea.
CA2381095A1 (en) Method for treating insulin resistance through hepatic nitric oxide
EA200200234A1 (en) PREPARATIONS FOR PARENTERAL APPLICATION OF ESTRAMUSTINES OF PHOSPHATE AND ALBUMIN
WO2001082795A3 (en) Magnetic resonance imaging agents for the delivery of therapeutic agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11; DUE TO LATE TRANSMITTAL BY THE RECEIVINGOFFICE

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999505819

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA